TABLE 3.
Comparison of nucleoside/nucleotide analog administration between HBV/B2- and HBV/C2-infected patientsa
| HBV subgenotype (n) | Lamivudine treatment |
Adefovir treatment |
Entecavir treatment |
Telbivudine treatment |
||||
|---|---|---|---|---|---|---|---|---|
| No. (%) of cases | Mean duration (mo) ± SD | No. (%) of cases | Mean duration (mo) ± SD | No. (%) of cases | Mean duration (mo) ± SD | No. (%) of cases | Mean duration (mo) ± SD | |
| B2 (550) | 368 (66.8) | 22.6 ± 19.6 | 377 (68.4) | 18.0 ± 13.6 | 59 (10.8) | 16.0 ± 9.6 | 52 (9.5) | 10.8 ± 6.7 |
| C2 (3,404) | 2,223 (65.3) | 24.9 ± 20.7 | 2220 (65.2) | 18.7 ± 14.4 | 428 (12.6) | 16.0 ± 11.5 | 322 (9.5) | 12.4 ± 10.2 |
| P | 0.464 | 0.237 | 0.127 | 0.591 | 0.222 | 0.601 | 0.997 | 0.538 |
a
Including monotherapy and sequential and combined therapies in various administration schedules. The duration that the patient was exposed to the individual drug was independently counted.